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To  the  Editor:  Mycobacterium 
haemophilum  is  an  aerobic,  slow-
growing  microorganism  with  optimal 
growth at 30°C to 32°C. It has a unique 
requirement for ferric iron–containing 
compounds (1), from which it acquired 
its  name  (i.e.,  haemophilum).  Infec-
tions  with  M.  haemophilum  are  rare, 
but cervicofacial lymphadenitis caused 
by M. haemophilum has been described 
in  children  (2).  Besides  cervicofacial 
lymphadenitis, extrapulmonary signs of 
M. haemophilum disease include sub-
cutaneous noduli, arthritis, and osteo-
myelitis, which generally affect immu-
nocompromised patients (3). Recently, 
2 cases of cutaneous M. haemophilum 
infections after alemtuzumab treatment 
were reported (4). A small number of 
pulmonary M. haemophilum infections 
associated with AIDS or solid organ or 
bone marrow transplantation have been 
described  (1).  We  report  pulmonary 
M. haemophilum infection in a wom-
an  who  had  been  immunosuppressed 
by tumor necrosis factor-α antagonist 
(TNF-αA) (adalimumab) treatment for 
rheumatoid arthritis.
A 72-year-old woman with a his-
tory  of  rheumatoid  arthritis  and  ob-
structive  sleep  apnea  syndrome  had 
signs and symptoms of fatigue, mild 
fever  episodes,  and  a  nonproductive 
cough  9  months  after  treatment  for 
rheumatoid  arthritis  had  begun  with 
methotrexate  (MTX)  and  TNF-αA. 
Physical examination was unremark-
able except for a body temperature of 
38.9°C. Laboratory testing showed an 
increased  erythrocyte  sedimentation 
rate (ESR) (77 mm/h), an increased C-
reactive protein (CRP) level (60 mg/L), 
a normal leukocyte count (8,500 cells/
μL), and relative monocytosis (12%). 
HIV  serologic  testing  results  were 
negative. Chest radiograph showed an 
infiltrate in the right upper lobe. Chest 
computed tomography confirmed this 
finding and showed lymphadenopathy 
in the right hilus and mediastinum.
Notably, the tuberculin skin test 
result  was  negative  at  screening  be-
fore she began the TNF-αA treatment, 
but was now positive (20 mm), sug-
gesting  mycobacterial  infection. Au-
ramine and Ziehl-Neelsen staining of 
sputum  and  bronchoalveolar  liquids 
showed  no  acid-fast  bacilli,  and  M. 
tuberculosis  infection  was  not  con-
firmed  by  PCR  or  culture.  Eventu-
ally, a mediastinal lymph node biopsy 
was  taken  by  endoscopic  ultrasound 
guidance.  Granulomatous  inflamma-
tion  and  acid-fast  bacilli  were  seen 
by  microscopy.  Corresponding  cul-
tures yielded a strain identified as M. 
haemophilum at the Netherlands Na-
tional Institute for Public Health and 
the Environment (RIVM) by using the 
Inno-LiPA  Mycobacteria  v2  reverse 
line blot assay (Innogenetics, Ghent, 
Belgium).  Strain  identity  was  con-
firmed by sequencing of the complete 
16S rDNA gene, which was identical 
to that of M. haemophilum available 
in  the  GenBank  sequence  database 
(National  Center  for  Biotechnology 
Information;  www.ncbi.nlm.nih.gov; 
accession no. X88923).
The RIVM performed drug sus-
ceptibility testing by using a modi-
fied agar dilution method (5). Mid-
dlebrook 7H10 media were enriched 
with  10%  sheep  blood  hemolyzed 
by 1:1 dilution with water and sub-
sequent  freezing–thawing.  Historic 
drug susceptibility data was reviewed 
(Table).  Initially,  adalimumab  was 
discontinued,  and  our  patient  was 
treated with isoniazid, ethambutol, ri-
fampin, and pyrazinimide because M. 
tuberculosis infection was suspected. 
After  identification  of  M.  haemo-
philum, our patient was treated with 
rifampin  and  azithromycin.  A  total 
treatment duration of 10 months re-
sulted in complete resolution of the 
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Table. Antimicrobial drug susceptibility test results for Mycobacterium haemophilum
isolate from rheumatoid arthritis patient and other M. haemophilum isolates* 
Case report  RIVM historic data (n = 49)  Antimicrobial
drug Classification  MIC, mg/L  % Susceptible  % Resistant 
Isoniazid Resistant 10 0 100
Rifampin Susceptible 0.2 4 96
Ethambutol Resistant 20 0 100
Streptomycin  Susceptible <1.0 35 65
Cycloserine  Susceptible 50 78 22
Prothionamide Susceptible <1.0 61 39
Amikacin Resistant 10 29 71
Ciprofloxacin Resistant 4.0 88 12
Clofazimine Susceptible <0.5 92 8
Clarithromycin  Susceptible <2.0 94 6
Rifabutin Susceptible <0.2 96 4
*All isolates submitted to the Mycobacteria Reference Laboratory, National Institute for Public Health 
and the Environment (RIVM), the Netherlands, January 2000–January 2007. Before January 2004, 
strains tested were identified by 16S rDNA gene sequencing; after January 2004, strains were 
identified by the Inno-LiPA assay (Innogenetics, Ghent, Belgium). LETTERS
pulmonary  infiltrate  and  normaliza-
tion of ESR and CRP concentration. 
During the follow- up period of >12 
months, the patient remained asymp-
tomatic. Her rheumatoid arthritis was 
treated with MTX monotherapy.
This case illustrates the risk for 
infectious  diseases  during  TNF-αA 
treatment.  Rheumatoid  arthritis  can 
be treated effectively with MTX and 
TNF-αA  (6).  Side  effects  of  con-
cern  are  infectious  diseases,  which 
prompt the need for screening for la-
tent  mycobacterial  infection  before 
commencing  treatment  (7).  Despite 
screening,  mycobacterial  infections 
have been diagnosed after prolonged 
treatment in various patients (8). This 
case shows that not only M. tubercu-
losis  but  also  nontuberculous  myco-
bacteria (NTM) should be considered 
as possible pathogens. This possibility 
is  of  clinical  importance  because  of 
the diagnostic challenges. Diagnosing 
NTM infections may require specific 
culture  media  and  molecular  assays. 
Under  optimal  conditions,  cultures 
show  growth  of  most  NTM  species 
(including M.  haemophilum) within 
2–3 weeks. NTM are less susceptible 
to antimicrobial drugs than M. tuber-
culosis. M.  haemophilum is generally 
resistant in vitro to isoniazid, etham-
butol, and rifampicin (Table), but no 
standardized  susceptibility  methods 
for M. haemophilum exist. Therefore, 
following current guidelines from the 
American Thoracic Society (ATS) is 
advisable for NTM infections (9).
No specific recommendations ex-
ist  for  pulmonary  M.  haemophilum 
infections,  but  for  disseminated  M. 
haemophilum infections, the ATS rec-
ommends a multidrug regimen com-
bining  clarithromycin,  rifampicin/
rifabutin, and ciprofloxacin. Although 
no studies on treatment duration for 
M. haemophilum infections have been 
conducted, the ATS guidelines recom-
mend  treatment  until  cultures  taken 
during therapy are negative for 1 year 
(9).  Whether  TNF-αA  treatment  can 
be continued during antimycobacterial 
treatment is a matter of debate in the 
absence of sufficient safety data (8). 
In active tuberculosis infection, treat-
ment with TNF-αA is contraindicated 
before  patients  complete  a  standard 
regimen  of  antituberculosis  therapy; 
no information is available for NTM 
disease (10).
This case is presented especially 
to  demonstrate  the  diagnostic  chal-
lenges  of  NTM  infections.  For  such 
cases, clinicians are advised to consult 
experts in the field of NTM infections.
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